UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                               ------------------

                                    FORM 8-K

                                 CURRENT REPORT
     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

        Date of report (Date of earliest event reported): April 15, 2005

                              --------------------

                              PharmaFrontiers Corp.
             (Exact Name of Registrant as Specified in Its Charter)


                                      Texas
                 (State or Other Jurisdiction of Incorporation)

                000-25513                                76-0333165
                ---------                                ----------
        (Commission File Number)            (I.R.S. Employer Identification No.)


    2408 Timberloch Place, Suite B-7
          The Woodlands, Texas                             77380
          --------------------                             -----
(Address of Principal Executive Offices)                 (Zip Code)


       Registrant's telephone number, including area code: (281) 272-9331

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[_]  Written communications pursuant to Rule 425 under the Securities Act (17
     CFR 230.425)

[_]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
     240.14a-12)

[_]  Pre-commencement communications pursuant to Rule 14d-2(b) under the
     Exchange Act (17 CFR 240.14d-2(b))

[_]  Pre-commencement communications pursuant to Rule 13e-4(c) under the
     Exchange Act (17 CFR 240.13e-4(c))








Item 8.01.  Other Events.

         On April 15, 2005, Registrant filed its Annual Report on Form 10-KSB
for the fiscal year ended December 31, 2004 and announced its results of
operations in a press release. A copy of the press release is attached as
Exhibit 99.1.


Item 9.01         Financial Statements and Exhibits

(c) Exhibit 99.1

The following exhibits are to be filed as part of this 8-K:


Exhibit No.          Description
- ----------           -----------
99.1                 Press release issued April 15, 2005


                                   SIGNATURES

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.




                                PHARMAFRONTIERS CORP.



                                By:  /s/ David McWilliams
                                -----------------------------------------
                                David McWilliams, Chief Executive Officer





DATE:  April 15, 2005









                                  EXHIBIT INDEX



Exhibit No.          Description
- -----------          -----------
99.1                 Press release issued April 15, 2005.